14159, L.P.
CIK 1551138 · last filed 2019-02-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACAD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | Director | 92,042 | $115.88 | $10.67M | $0 | 6 | 2019-02-27 |
| Aceragen, Inc. (IDRA) Delisted | Director | 251,992 | $7.22 | $1.82M | $0 | 2 | 2019-01-04 |
| ACAD | Director | 24,667,110 | $19.69 | $485.70M | $459.53M | 2 | 2018-09-24 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 204,452 | — | — | $223.55M | 7 | 2017-10-03 |
| XOMA Royalty Corp (XOMA) Delisted | Director | 870,308 | $40.17 | $34.96M | -$92.18M | 2 | 2014-12-10 |
| Seagen Inc. (SGEN) Delisted | Director | 3,949,073 | $228.74 | $903.31M | $113.02M | 1 | 2013-12-16 |
| BCRX | 10%+ Owner | 1,642,513 | $7.59 | $12.47M | $50.00M | 1 | 2013-08-02 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 207,820 | — | — | $146.01M | 1 | 2012-07-13 |
Recent Filings · Page 2 of 3
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-05-12 | INCY | Exer (M) | +420,000 | $3.23M | EDGAR |
| 2014-12-10 | XOMA Royalty Corp (XOMA) Delisted | Sell (S) | −2,746,471 | -$12.68M | EDGAR |
| 2014-12-04 | XOMA Royalty Corp (XOMA) Delisted | Sell (S) | −16,605,442 | -$79.50M | EDGAR |
| 2014-07-03 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | +129,822 | $367.4K | EDGAR |
| 2013-12-16 | Seagen Inc. (SGEN) Delisted | Buy (P) | +2,849,546 | $113.02M | EDGAR |
| 2013-08-02 | BCRX | Buy (P) | +11,363,640 | $50.00M | EDGAR |
| 2013-06-13 | INCY | Exer (M) | +180,000 | $799.2K | EDGAR |
| 2013-05-14 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +1,442,556 | $49.54M | EDGAR |
| 2013-02-11 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +698,160 | $19.65M | EDGAR |
| 2012-11-14 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +4,942,632 | $137.45M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.